Lund, Sweden — Camurus AB (Nasdaq Stockholm; CAMX) today announces that they will host a Capital Markets Day on 14th December in Stockholm.
Presentations will be made by President and CEO Fredrik Tiberg and parts of Camurus management team and Behshad Sheldon, CEO Braeburn Pharmaceuticals.
Time: Wednesday 14 December, 1.30pm – 5.00pm CET
Venue: IVA Conference Center, Grev Turegatan 16, Stockholm
Invitation for: Institutional investors, analysts and media
Registration for investors, analysts and journalists
To participate, please register no later than 9 December at; CMD@camurus.com
A detailed program will be posted in mid-November on Camurus website www.camurus.com.
For more information please contact:
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
The information was submitted for publication at 07.00 a.m. CET on 1 November 2016.